Safety of denosumab in giant-cell tumour of bone

The Lancet Oncology

Volumn 11, Issue 9, 2010, Pages 815-

  Thomas, David ^a   Carriere, Phillipe ^b   Jacobs, Ira ^b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENOSUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR;

BONE TUMOR; CRITERION VARIABLE; DIAGNOSTIC VALUE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; GIANT CELL TUMOR; HUMAN; INFORMATION DISSEMINATION; INFORMED CONSENT; JAW OSTEONECROSIS; LETTER; MEDICAL EDUCATION; MOUTH EXAMINATION; PHYSICIAN; PRIORITY JOURNAL; RISK FACTOR; BONE NECROSIS; BONE NEOPLASMS; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); GIANT CELL TUMOR OF BONE; JAW DISEASE; SAFETY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CLINICAL TRIALS AS TOPIC; GIANT CELL TUMOR OF BONE; HUMANS; JAW DISEASES; OSTEONECROSIS; RANK LIGAND; SAFETY;

EID: 77956148435     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70170-4     Document Type: Letter

References (2)

1. Kyrgidis A, Toulis K Safety and efficacy of denosumab in giant-cell tumour of bone. Lancet Oncol 2010, 11:513-514.
2. Thomas D, Henshaw R, Skubitz K, et al. Denosumab in patients with giant-cell tumour of bone: an open label, phase 2 study. Lancet Oncol 2010, 11:275-280.